Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial - Wikidata - wikimedia - TriplyDB

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

http://www.wikidata.org/entity/Q35859030

about

Clinical management of localized colon cancer with capecitabine A feasibility trial of postoperative adjuvant chemotherapy with S-1, an oral fluoropyrimidine, for elderly patients with non-small cell lung cancer: a report of the Lung Oncology Group in Kyushu (LOGIK) protocol 0901.Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial).Efficacy of S-1 in colorectal cancer.Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients.Neoadjuvant chemotherapy followed by surgery versus surgery alone for colorectal cancer: meta-analysis of randomized controlled trials.From Evidence-based Medicine to Personalized Medicine Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial.Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.Thymidine phosphorylase mRNA expression may be a predictor of response to post-operative adjuvant chemotherapy with S-1 in patients with stage III colorectal cancer.Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer

P2860

Q24611758-5D753263-2254-475F-BCE4-ECDA6383AE55 Q33405513-7D15FD65-74D1-4C47-8FD9-23DB2A0AD8B3 Q33646009-3317ACE6-86F6-4098-B8B3-C814B093B8D3 Q33656724-71D1CCA5-1CBA-4BDF-BD12-F069B90BECB4 Q33840352-55F89E83-F8D8-4A4D-95FA-24077603C3A0 Q34000605-E325020E-83D7-41DE-997F-64E25FECFA00 Q34083135-1D89B0CD-F4FE-4453-951A-7ADE07130D07 Q34429445-77277DC4-F96A-46E5-B222-4DAEE5EF4BCE Q34636336-A87450B8-8DBC-4063-A750-2F5696F809BE Q35996020-71F76216-559C-46F1-900C-B9F8EBB78B6C Q36153879-EC880219-FC15-4020-9C93-2440E62AC09B Q36403027-CC5EA7C3-B0EE-4739-BE5A-23E92CD81979 Q36588752-51C433EF-8296-478B-8803-B2D880858FF7 Q37405954-94967A33-4A3F-49BC-9B79-B00C79C9449A Q38619215-4A71CD9F-5EB0-481C-AED0-B6A81957B702 Q39786290-49717173-D8FD-4A66-BEB9-EA143CCFDE4C Q42123010-0D8A4F4D-4877-46D8-827B-44E4C8226594 Q45735746-612BF93B-6A14-4A57-A717-6481DCE4CAF3 Q58694209-8A640BE2-4189-4780-B0CE-FBEAD516DEB3

P2860

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial

http://www.wikidata.org/entity/Q35859030

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@ast

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@en

type

label

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@ast

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@en

prefLabel

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@ast

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@en

P1433

Q35859030-D0D276A3-6CD7-4B68-A4E6-06DF68D304CE

P1476

Q35859030-EF8C5B90-57A4-4AF6-A8CA-07D4686D2203

P2093

Q35859030-1BA35B08-EBD1-4657-9AFB-5CD34E5F5BA0

Q35859030-22C74146-0058-4428-AFEF-340718ECC078

Q35859030-25C39FED-27F5-4478-9E98-8E0EC4F65F0B

Q35859030-286A4A06-4377-4137-8BF1-12F20FC9732A

Q35859030-29F4F65F-33EA-4411-BC28-C276887FF288

Q35859030-365AA39B-4C52-48E9-B304-8567C4AD45B3

Q35859030-44C40EF3-8E46-4282-9747-2883A075345D

Q35859030-5285C3BF-BFB9-4DFB-A201-CB96F1375BBC

Q35859030-5C48217E-89A2-428E-8184-2EC8EF964596

Q35859030-83B12DC0-D174-4A2B-8AA7-183CA077A9AB

P2860

Q35859030-1F2BD24E-D14B-463D-ABD3-005C4C6AC085

Q35859030-3FA762C6-78D2-4E7B-A89A-3CE0856BD508

Q35859030-7C2DE982-2B47-42F7-B4D1-F9422112FD3F

Q35859030-B4596CEB-0CDB-49BF-BBE1-5E398ADF796C

Q35859030-BAE98593-F8C4-4BE0-97D8-B082B15C0C22

Q35859030-CBE48662-C3D8-4030-BB8D-FD07E5C71476

Q35859030-CFA2BB45-E4A7-4CD2-A826-3A38E8395754

Q35859030-D22D95E4-9C3E-4AD9-9357-C2DF0F07A595

Q35859030-DDB19FBE-23DD-4761-B93C-FCD1054787A0

P2888

Q35859030-80AE00D3-1DD8-4285-91CC-4DF0C3D351F3

P304

Q35859030-B6934C73-4858-4B12-A13C-FC9311EEAD3C

P31

Q35859030-20EBBB5A-087E-490F-B041-0D4290E75186

P356

Q35859030-4964B81B-F2D1-4AF0-AA53-5105A8612986

P407

Q35859030-3276A940-4292-49BC-B128-E542687F22B4

P433

Q35859030-155DEF6D-D3DC-4CEC-9BD5-C371143D3A15

P478

Q35859030-A1DFF616-0C94-4890-8FB7-A5C216AD74C9

P50

Q35859030-DC61D9AD-A07D-4E57-8499-9083AF69A0BF

P577

Q35859030-098899DB-EE45-4730-B671-B475EAC30D05

P5875

Q35859030-00BB3C28-6F23-48AA-B4C2-1F2680D68740

P698

Q35859030-A7520340-7982-4D7F-8107-CD2DC5947E96

P921

Q35859030-95B69C58-3F00-4485-8332-9859748BB138

P932

Q35859030-DB7D5405-6494-4EC5-A58D-6C4205DFA026

P356

P1433

British Journal of Cancer

P1476

Safety of UFT/LV and S-1 as ad ...... phase III trial: ACTS-CC trial

@en

P2093

A Takagane

http://www.w3.org/2001/XMLSchema#string

H Mochizuki

http://www.w3.org/2001/XMLSchema#string

H Shinozaki

http://www.w3.org/2001/XMLSchema#string

H Takiuchi

http://www.w3.org/2001/XMLSchema#string

I Mochizuki

http://www.w3.org/2001/XMLSchema#string

K Ikejiri

http://www.w3.org/2001/XMLSchema#string

K Sugihara

http://www.w3.org/2001/XMLSchema#string

K Takahashi

http://www.w3.org/2001/XMLSchema#string

M Watanabe

http://www.w3.org/2001/XMLSchema#string

N Boku

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV

Revised TN categorization for colon cancer based on national survival outcomes data.

Capecitabine as adjuvant treatment for stage III colon cancer.

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Potential regional differences for the tolerability profiles of fluoropyrimidines.

Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up

P2888

P304

1268-1273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.86

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221893178

http://www.w3.org/2001/XMLSchema#string

P698

22415232

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

3314794

http://www.w3.org/2001/XMLSchema#string